The FDA has approved Enspryng (satralizumab, Genentech) for thyroid eye disease (TED), making the drug the first subcutaneous ...
Noah Banoub, a third year medical student, describes his journey into medicine and his choice of specialty. He recounted how MacTel type 2 went from being a diagnosis of exclusion without a therapy to ...
Eclipse Life Sciences reports that its biodegradable 6-month fluocinolone acetonide implant met its primary safety end point ...
Restoring sight after whole human eye transplant remains a long-term goal, and the optic nerve is the limiting factor, ...
OT Roundup covers the optogenetics Nobel Prize, remigromig in DME with Veeral Sheth, MD, Stargardt disease and a total human ...
At AAO 2026, Adam, MD, shares Yamane technique pearls, from docking the trailing haptic to preventing tilt and haptic ...
Alvotech and Advanz Pharma have submitted a European regulatory application for AVT29, a proposed biosimilar to high-dose ...
At AAO 2026, Michael T. Yen, MD, explained how at-home subcutaneous elegrobart could ease treatment burden in thyroid eye ...
Innovation in therapeutics has a lot on the horizon, he said, but all of those drugs and innovations can only be delivered by ...
Jacque Duncan, MD, reviews phase 3 DRAGON data on oral tinlarebant for Stargardt disease and its mechanism-related visual ...
The underlying field was recognized this week when the 2026 Nobel Prize in Physiology or Medicine went to Karl Deisseroth, MD ...
In addition to the results, Roche also announced that the US Food and Drug Administration (FDA) has accepted the company’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results